Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Blood

Volumn 120, Issue 3, 2012, Pages 560-568

  Gopal, Ajay K ^a   Ramchandren, Radhakrishnan ^b   O'Connor, Owen A ^c   Berryman, Robert B ^d   Advani, Ranjana H ^e   Chen, Robert ^f   Smith, Scott E ^g   Cooper, Maureen ^h   Rothe, Achim ⁱ   Matous, Jeffrey V ^j   Grove, Laurie E ^k   Zain, Jasmine ^l  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g LOYOLA UNIVERSITY CHICAGO   (United States)

^h St Francis Hospital and Health Care Centers   (United States)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j Rocky Mountain Blood and Marrow Transplant Program   (United States)

^k SEATTLE GENETICS INC   (United States)

^l NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; BENDAMUSTINE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; NAVELBINE; PHOSPHATE; PREDNISONE; PROCARBAZINE; THYMOCYTE ANTIBODY; VINBLASTINE; VINCRISTINE;

ABNORMAL LABORATORY RESULT; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADVERSE DRUG REACTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BACTEREMIA; BRAIN HEMORRHAGE; CANCER SURVIVAL; CHILL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; COUGHING; CYTOMEGALOVIRUS INFECTION; DECREASED APPETITE; DIARRHEA; DONOR LYMPHOCYTE INFUSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GANGRENE; GRAFT VERSUS HOST REACTION; HEADACHE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLUENZA A (H1N1); INFUSION RELATED REACTION; LEUKOCYTE; LUNG ASPERGILLOSIS; LYMPHOCYTE; MALE; METABOLIC ACIDOSIS; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OROPHARYNX PAIN; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PSEUDOMONAS PNEUMONIA; RECURRENT CANCER; RESPIRATORY ACIDOSIS; SENSORY NEUROPATHY; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIREMIA; VIRUS REACTIVATION; VOMITING;

EID: 84864132475     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-397893     Document Type: Article

References (28)

1. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
2. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348(24):2386-2395. (Pubitemid 36682817)
3. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol. 2002;20(1):221-230. (Pubitemid 34032615)
4. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-2071. (Pubitemid 34680969)
5. Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer. 2003; 97(11):2748-2759. (Pubitemid 36605142)
6. Gopal AK, Metcalfe TL, Gooley TA, et al. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer. 2008;113(6):1344-1350.
7. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934-4937.
8. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18- fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102(1):53-59. (Pubitemid 36759635)
9. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005; 16(4):625-633.
10. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following non-myeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279- 1287.
11. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006; 38(3):211-216.
12. Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010; 115(18):3671-3677.
13. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455-462. (Pubitemid 351171699)
14. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94(2):230-238.
15. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14(4):418-425. (Pubitemid 351372748)
16. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007; 21(11):2316-2323. (Pubitemid 350011704)
17. Ram R, Gooley TA, Maloney DG, et al. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17(10):1537-1545.
18. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective anti-tumor activity. Blood. 2003;102(4):1458-1465. (Pubitemid 36988057)
19. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540-10547. (Pubitemid 43864594)
20. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30- positive lymphomas. N Engl J Med. 2010; 363(19):1812-1821.
21. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
22. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
23. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
24. Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant. 2011; 17(10):1497-1504.
25. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934- 1941.
26. ADCETRIS (brentuximab vedotin) for injection [package insert]. Bothell, WA: Seattle Genetics, Inc; 2012.
27. Blazar BR, Levy RB, Mak TW, et al. CD30/CD30 ligand (CD153) interaction regulates CD4+T cell-mediated graft-versus-host disease. J Immunol. 2004;173(5):2933-2941. (Pubitemid 39141997)
28. D'Elios MM, Romagnani P, Scaletti C, et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol. 1997;61(5):539-544. (Pubitemid 27234449)